OGX-011 clinical trials
Also written OGX-011, custirsen sodium and TV-1011.
How each study uses OGX-011 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2012 (3)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 2 |
| 2006 | 1 |
| 2010 | 2 |
| 2012 | 3 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 2
Achieve Life Sciences (8) · NCIC Clinical Trials Group (1) · University of British Columbia (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses OGX-011 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung CancerCompletedPhase 3Achieve Life SciencesNCT01630733Written as CustirsenHow we know
- Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone TherapyCompletedPhase 2NCIC Clinical Trials GroupNCT00258388Written as custirsen sodiumHow we know
- Study of OGX-011 Given Prior to Radical Prostatectomy in Patients With Localized Prostate CancerCompletedPhase 2University of British ColumbiaNCT00138918Written as OGX-011How we know
- Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate CancerCompletedPhase 3Achieve Life SciencesNCT01188187Written as CustirsenHow we know
- Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate CancerCompletedPhase 3Achieve Life SciencesNCT01578655Written as custirsen sodiumHow we know
- A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)TerminatedPhase 3Achieve Life SciencesNCT01083615Written as custirsen sodiumHow we know
- Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac RepolarizationCompletedPhase 1Achieve Life SciencesNCT01874561Written as CustirsenHow we know
- A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment RegimenCompletedPhase 1Achieve Life SciencesNCT01497470Written as Custirsen, paclitaxel and carboplatinHow we know
- Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPCCompletedPhase 2Achieve Life SciencesNCT00327340Written as custirsen (OGX-011)/mitoxantroneHow we know
- A Study of OGX-011/Gemcitabine/Platinum-Based Regimen in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1/2Achieve Life SciencesNCT00138658Written as custirsen sodiumHow we know
Codes
What other systems call OGX-011 · ClinicalTrials.gg INT004812
Also registered as custirsen (UNII L26E95NLRK) and custirsen sodium (UNII ILE26V76EB).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.